Compulsory licensing of patents.

IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI:10.4155/ppa-2022-0039
Narayanasamy Kumutha, Narayanasamy Amutha, Govindasamy S Venkatesh
{"title":"Compulsory licensing of patents.","authors":"Narayanasamy Kumutha,&nbsp;Narayanasamy Amutha,&nbsp;Govindasamy S Venkatesh","doi":"10.4155/ppa-2022-0039","DOIUrl":null,"url":null,"abstract":"<p><p>Compulsory licensing (CL) is a mechanism made by the government to provide balance between the monopoly right holders and the third person with public interest by ensuring the ease availability of the patented products at reasonable rate. This paper discusses the background criteria for getting CL in India as per the Indian Patent Act, 1970 starting from the concepts outlined in the Trade-Related Aspects of Intellectual Property Rights agreement. We reviewed the case studies for the accepted and rejected CL in India. We also discuss important CL cases that were permitted internationally, including the present COVID pandemic CL. Finally, we provide our analytical perspectives regarding the pros and cons of CL.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/ppa-2022-0039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 5

Abstract

Compulsory licensing (CL) is a mechanism made by the government to provide balance between the monopoly right holders and the third person with public interest by ensuring the ease availability of the patented products at reasonable rate. This paper discusses the background criteria for getting CL in India as per the Indian Patent Act, 1970 starting from the concepts outlined in the Trade-Related Aspects of Intellectual Property Rights agreement. We reviewed the case studies for the accepted and rejected CL in India. We also discuss important CL cases that were permitted internationally, including the present COVID pandemic CL. Finally, we provide our analytical perspectives regarding the pros and cons of CL.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
专利的强制许可。
强制许可是政府制定的一种机制,旨在通过确保专利产品以合理的价格易于获得,从而在垄断权持有人和具有公共利益的第三人之间取得平衡。本文从《与贸易有关的知识产权协定》中概述的概念出发,讨论了根据1970年《印度专利法》在印度获得CL的背景标准。我们回顾了印度接受和拒绝CL的案例研究。我们还讨论了国际上允许的重要CL病例,包括目前的COVID大流行CL。最后,我们就CL的利弊提供了我们的分析观点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmaceutical patent analyst
Pharmaceutical patent analyst PHARMACOLOGY & PHARMACY-
CiteScore
1.80
自引率
0.00%
发文量
22
期刊最新文献
Liraglutide innovations: a comprehensive review of patents (2014–2024) Esterase responsive release of anti-cancer agents from conjugated lipid nanocarrier and the regulatory considerations Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency Patent highlights August-September 2023. Patent Highlights June-July 2023.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1